Literature DB >> 19648826

Accuracy and complexities of using automated clinical data for capturing chemotherapy administrations: implications for future research.

Erin J Aiello Bowles1, Leah Tuzzio, Debra P Ritzwoller, Andrew E Williams, Tyler Ross, Edward H Wagner, Christine Neslund-Dudas, Andrea Altschuler, Virginia Quinn, Mark Hornbrook, Larissa Nekhlyudov.   

Abstract

BACKGROUND: Chemotherapy data are important to almost any study on cancer prognosis and outcomes. However, chemotherapy data obtained from tumor registries may be incomplete, and abstracting chemotherapy directly from medical records can be expensive and time consuming.
METHODS: We evaluated the accuracy of using automated clinical data to capture chemotherapy administrations in a cohort of 757 ovarian cancer patients enrolled in 7 health plans in the HMO Cancer Research Network. We calculated sensitivity and specificity with 95% confidence intervals of chemotherapy administrations extracted from 3 automated clinical data sources (Health Care Procedure Coding System, National Drug Codes, and International Classification of Diseases) compared with tumor registry data and medical chart data.
RESULTS: Sensitivity of all 3 data sources varied across health plans from 79.4% to 95.2% when compared with tumor registries, and 75.0% to 100.0% when compared with medical charts. The sensitivities using a combination of 3 data sources were 88.6% (95% confidence intervals: 85.7-91.1) compared with tumor registries and 89.5% (78.5-96.0) compared with medical records; specificities were 91.5% (86.4-95.2) and 90.0% (55.5-99.7), respectively. There was no difference in accuracy between women aged < 65 and > or = 65 years. Using one set of codes alone (eg, Health Care Procedure Coding System alone) was insufficient for capturing chemotherapy data at most health plans.
CONCLUSIONS: While automated data systems are not without limitations, clinical codes used in combination are useful in capturing chemotherapy more comprehensively than tumor registry and without the need for costly medical record abstraction. Key Words: validation of automated clinical data, chemotherapy, medical chart, tumor registry, ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19648826      PMCID: PMC2764807          DOI: 10.1097/MLR.0b013e3181a7e569

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  11 in total

1.  Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Authors:  Joan L Warren; Carrie N Klabunde; Deborah Schrag; Peter B Bach; Gerald F Riley
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

2.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Authors:  Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

3.  External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews.

Authors:  Xianglin L Du; Charles R Key; Lois Dickie; Ronald Darling; Jane M Geraci; Dong Zhang
Journal:  Med Care       Date:  2006-02       Impact factor: 2.983

4.  Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews.

Authors:  Xianglin L Du; Charles R Key; Lois Dickie; Ronald Darling; George L Delclos; Kim Waller; Dong Zhang
Journal:  J Clin Epidemiol       Date:  2005-09-30       Impact factor: 6.437

5.  Building a virtual cancer research organization.

Authors:  Mark C Hornbrook; Gene Hart; Jennifer L Ellis; Donald J Bachman; Gary Ansell; Sarah M Greene; Edward H Wagner; Roy Pardee; Mark M Schmidt; Ann Geiger; Amy L Butani; Terry Field; Hassan Fouayzi; Irina Miroshnik; Liyan Liu; Robert Diseker; Karen Wells; Rick Krajenta; Lois Lamerato; Christine Neslund Dudas
Journal:  J Natl Cancer Inst Monogr       Date:  2005

Review 6.  Building a research consortium of large health systems: the Cancer Research Network.

Authors:  Edward H Wagner; Sarah M Greene; Gene Hart; Terry S Field; Suzanne Fletcher; Ann M Geiger; Lisa J Herrinton; Mark C Hornbrook; Christine C Johnson; Judy Mouchawar; Sharon J Rolnick; Victor J Stevens; Stephen H Taplin; Dennis Tolsma; Thomas M Vogt
Journal:  J Natl Cancer Inst Monogr       Date:  2005

7.  Completeness of information on adjuvant therapies for colorectal cancer in population-based cancer registries.

Authors:  Rosemary D Cress; Alan M Zaslavsky; Dee W West; Robert E Wolf; Martha C Felter; John Z Ayanian
Journal:  Med Care       Date:  2003-09       Impact factor: 2.983

8.  Second-line and third-line chemotherapy for lung cancer: use and cost.

Authors:  Scott D Ramsey; Renato G Martins; David K Blough; Lauri S Tock; Deborah Lubeck; Carolina M Reyes
Journal:  Am J Manag Care       Date:  2008-05       Impact factor: 2.229

9.  Managed care and cancer outcomes for Medicare beneficiaries with disabilities.

Authors:  Richard G Roetzheim; Thomas N Chirikos; Kristen J Wells; Ellen P McCarthy; Long H Ngo; Donglin Li; Reed E Drews; Lisa I Iezzoni
Journal:  Am J Manag Care       Date:  2008-05       Impact factor: 2.229

10.  Utility of the SEER-Medicare data to identify chemotherapy use.

Authors:  Joan L Warren; Linda C Harlan; Angela Fahey; Beth A Virnig; Jean L Freeman; Carrie N Klabunde; Gregory S Cooper; Kevin B Knopf
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

View more
  14 in total

1.  Validation of electronic data on chemotherapy and hormone therapy use in HMOs.

Authors:  Debra P Ritzwoller; Nikki Carroll; Thomas Delate; Maureen O'Keeffe-Rossetti; Paul A Fishman; Elizabeth T Loggers; Erin J Aiello Bowles; Jennifer Elston-Lafata; Mark C Hornbrook
Journal:  Med Care       Date:  2013-10       Impact factor: 2.983

Review 2.  Cancer research network: using integrated healthcare delivery systems as platforms for cancer survivorship research.

Authors:  Larissa Nekhlyudov; Sarah M Greene; Jessica Chubak; Borsika Rabin; Leah Tuzzio; Sharon Rolnick; Terry S Field
Journal:  J Cancer Surviv       Date:  2012-12-14       Impact factor: 4.442

3.  Algorithm to Identify Systemic Cancer Therapy Treatment Using Structured Electronic Data.

Authors:  Nikki M Carroll; Kate M Burniece; Jeff Holzman; Deanna B McQuillan; Angela Plata; Debra P Ritzwoller
Journal:  JCO Clin Cancer Inform       Date:  2017-11

4.  A framework for understanding cancer comparative effectiveness research data needs.

Authors:  William R Carpenter; Anne-Marie Meyer; Amy P Abernethy; Til Stürmer; Michael R Kosorok
Journal:  J Clin Epidemiol       Date:  2012-11       Impact factor: 6.437

5.  Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure.

Authors:  Thomas Delate; Erin J Aiello Bowles; Roy Pardee; Robert D Wellman; Laurel A Habel; Marianne Ulcickas Yood; Larissa Nekhlyudov; Katrina A Goddard; Robert L Davis; Catherine A McCarty; Adedayo A Onitilo; Heather Spencer Feigelson; Jared Freml; Edward Wagner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02-15       Impact factor: 4.254

6.  Hospital utilization and characteristics of patients experiencing recurrent readmissions within children's hospitals.

Authors:  Jay G Berry; David E Hall; Dennis Z Kuo; Eyal Cohen; Rishi Agrawal; Chris Feudtner; Matt Hall; Jacqueline Kueser; William Kaplan; John Neff
Journal:  JAMA       Date:  2011-02-16       Impact factor: 56.272

7.  Hospitalization Risk During Chemotherapy for Advanced Cancer: Development and Validation of Risk Stratification Models Using Real-World Data.

Authors:  Gabriel A Brooks; Hajime Uno; Erin J Aiello Bowles; Alexander R Menter; Maureen O'Keeffe-Rosetti; Anna N A Tosteson; Debra P Ritzwoller; Deborah Schrag
Journal:  JCO Clin Cancer Inform       Date:  2019-04

Review 8.  Data for cancer comparative effectiveness research: past, present, and future potential.

Authors:  Anne-Marie Meyer; William R Carpenter; Amy P Abernethy; Til Stürmer; Michael R Kosorok
Journal:  Cancer       Date:  2012-04-19       Impact factor: 6.860

9.  Predicting neutropenia risk in patients with cancer using electronic data.

Authors:  Pamala A Pawloski; Avis J Thomas; Sheryl Kane; Gabriela Vazquez-Benitez; Gary R Shapiro; Gary H Lyman
Journal:  J Am Med Inform Assoc       Date:  2017-04-01       Impact factor: 4.497

10.  Diffusion of Intraperitoneal Chemotherapy in Women with Advanced Ovarian Cancer in Community Settings 2003-2008: The Effect of the NCI Clinical Recommendation.

Authors:  Erin J Aiello Bowles; Karen J Wernli; Heidi J Gray; Andy Bogart; Thomas Delate; Maureen O'Keeffe-Rosetti; Larissa Nekhlyudov; Elizabeth Trice Loggers
Journal:  Front Oncol       Date:  2014-03-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.